10-K: Perceptive Capital Solutions Corp Files 10-K, Details Freenome Merger Progress Amid Going Concern Warning

Perceptive Capital Solutions Corp (PCSC) filed its annual 10-K report for the fiscal year ended December 31, 2025, detailing its proposed business combination with Freenome and highlighting a going concern uncertainty.

Summary

• Perceptive Capital Solutions Corp (PCSC) is a blank check company (SPAC) incorporated on March 22, 2024, with no operating revenues to date, focusing on the healthcare or healthcare-related industries.
• A Business Combination Agreement was entered into with Freenome Holdings, Inc. on December 5, 2025, with the proposed merger expected to close in the first half of 2026, subject to shareholder and customary approvals.
• Upon closing of the business combination, PCSC will domesticate to Delaware and change its name to Freenome, Inc. (New Freenome).
• A Private Investment in Public Equity (PIPE) Financing of $240,000,000 was secured through subscription agreements with qualified institutional buyers, institutional accredited investors, and existing Freenome stockholders, including an affiliate of the sponsor.
• The company reported a net income of $837,468 for the year ended December 31, 2025, primarily from $3,821,319 in interest income on investments held in the Trust Account, partially offset by operating costs of $2,980,553.
• As of December 31, 2025, the company held $91,872,418 in the Trust Account and $865,031 in operating cash, but had a working capital deficit of $1,346,674.
• The independent registered public accounting firm's report includes an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern due to liquidity needs and the mandatory liquidation date of June 13, 2026, if a business combination is not completed.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with caution due to the explicit 'going concern' warning from auditors and the significant working capital deficit, despite the progress on the Freenome business combination and successful PIPE financing. The inherent risks of SPACs and the mixed performance of prior management SPACs also contribute to a moderate-to-negative sentiment.

Positives

• Secured a Business Combination Agreement with Freenome Holdings, Inc., a target in the life sciences and medical technology sectors, aligning with the management team's expertise.
• Successfully raised $240,000,000 through a PIPE Financing, demonstrating investor confidence in the proposed merger, with participation from an affiliate of the sponsor.
• The management team possesses extensive experience in the healthcare industry and a track record of executing prior SPAC business combinations, including successful exits like Cerevel Therapeutics.
• Reported a net income of $837,468 for the year ended December 31, 2025, primarily due to interest income generated from funds held in the Trust Account.
• The Trust Account holds a substantial $91,872,418 as of December 31, 2025, providing significant capital for the completion of the business combination.

Negatives

• The independent auditor's report contains an explanatory paragraph expressing "substantial doubt about our ability to continue as a going concern" due to insufficient liquidity and the mandatory liquidation deadline.
• A working capital deficit of $1,346,674 as of December 31, 2025, indicates that the company does not have sufficient funds for its working capital needs for at least one year without additional financing.
• The company has no operating history and has not generated any operating revenues to date, relying solely on interest income from the Trust Account.
• The Proposed Freenome Business Combination is subject to numerous conditions and risks, and there is no assurance that it will be completed.
• If the business combination is not completed by June 13, 2026, the company will be forced to liquidate, and public shareholders may receive only approximately $10.00 per share, or potentially less, on redemption.
• Potential for significant dilution to existing shareholders if additional shares are issued at a price less than $10.00 per share in connection with the business combination or related financing.

Risks

• The Proposed Freenome Business Combination may not be completed on the terms or timeline currently contemplated, or at all, due to numerous conditions and potential termination, which could adversely affect the company's business and share price.
• The company has no operating history and no revenues, providing no basis to evaluate its ability to achieve its business objective, and will never generate operating revenues if the business combination fails.
• The independent registered public accounting firm's report contains an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern due to liquidity needs and the mandatory liquidation date of June 13, 2026.
• Shareholders may not be afforded an opportunity to vote on the proposed business combination, and even if a vote is held, the sponsor and management team's agreement to vote in favor increases the likelihood of approval regardless of public shareholder sentiment.
• Third parties may bring claims against the company, potentially reducing the proceeds held in the Trust Account and resulting in public shareholders receiving less than $10.00 per share upon redemption.
• Nasdaq may delist the Class A ordinary shares from trading if listing standards are not maintained, which could limit investors' ability to transact in securities and subject the company to additional trading restrictions.
• The ability of public shareholders to redeem their shares for cash may make the company's financial condition unattractive to potential business combination targets, making it difficult to secure a merger.
• The issuance of additional Class A ordinary shares or preference shares to complete the business combination or under an employee incentive plan could significantly dilute the equity interest of existing investors.
• Shares issued to investors in connection with the business combination, such as PIPE transactions, may be priced below $10.00 or the prevailing market price, further diluting existing shareholders and potentially reducing the trading price.
• Resources could be wasted in researching acquisitions that are not completed, materially adversely affecting subsequent attempts to locate and acquire another business.
• The company may have a limited ability to assess the management of a prospective target business, potentially leading to a business combination with a company whose management lacks the skills or qualifications for a public company.
• Incurring substantial debt to complete a business combination could adversely affect the company's leverage and financial condition, negatively impacting the value of shareholders' investment.
• The company's lack of business diversification post-combination, being solely dependent on a single business, may subject it to numerous economic, competitive, and regulatory developments.
• Pursuing business combination opportunities with a high degree of complexity that require significant operational improvements could delay or prevent the achievement of desired results.
• Shareholders may be held liable for claims by third parties against the company to the extent of distributions received by them upon redemption of their shares if the company enters into an insolvent liquidation.
• The company may not hold an annual meeting of shareholders until after the consummation of its initial business combination, limiting public shareholders' ability to elect directors and discuss company affairs with management.
• The healthcare industry, the company's target sector, is subject to extensive governmental regulation, cost control pressures, and risks related to drug/device approval, patent expiration, and product liability.
• Macro-economic turbulence and instability, including geopolitical conflicts (Russia-Ukraine, Israel-Iran/Hamas), inflation, rising interest rates, and changes in trade policies/tariffs, may adversely affect the company's business and ability to complete a business combination.
• The securities in which funds are held in the Trust Account could bear a negative rate of interest, potentially reducing the per-share redemption amount received by public shareholders to less than $10.00.
• Provisions in the amended and restated memorandum and articles of association may inhibit a takeover, potentially limiting the future price investors might be willing to pay for Class A ordinary shares and entrenching management.
• Incorporation under Cayman Islands law may limit shareholders' ability to protect their interests and enforce rights through U.S. federal courts.
• The company has been a passive foreign investment company (PFIC), which could result in adverse U.S. federal income tax consequences to U.S. investors.
• A 1% U.S. federal excise tax on stock buybacks could be imposed on redemptions of shares if the company becomes a covered corporation, potentially reducing cash available for redemptions or the target business.
• The business combination or reincorporation may not be tax-efficient for shareholders, potentially requiring them to recognize taxable income.
• Changes in laws or regulations, or a failure to comply with them, including the 2024 SPAC Rules, may adversely affect the business, its ability to complete a business combination, and results of operations.
• If the company pursues a target with operations outside the United States, it may face additional burdens and risks associated with cross-border business operations, currency fluctuations, and differing legal systems.
• Conflicts of interest may arise from executive officers and directors allocating their time to other businesses and having fiduciary or contractual obligations to other entities, including other blank check companies or affiliated investment funds.
• The low price paid by the sponsor, officers, and directors for Founder Shares creates an incentive to complete a transaction even if the acquisition target subsequently declines in value and is unprofitable for public shareholders.

Future Outlook

The Proposed Freenome Business Combination is expected to close in the first half of 2026, contingent on shareholder and customary closing conditions. The company intends to utilize the funds held in the Trust Account to complete this combination and subsequently finance the operations or growth of the target business. Management plans to address the current going concern uncertainty through the successful consummation of this business combination.

Management Comments

• Our management team has previous experience in the execution of public acquisition vehicles.
• We believe our management team is well positioned to identify unique opportunities in our target sectors.
• We believe that the funds available to us outside of the Trust Account, together with funds available from loans from our sponsor, members of our management team or any of their affiliates... will be sufficient to allow us to operate until we are required to liquidate...
• Management plans to complete the initial Business Combination prior to the mandatory liquidation date and expects to receive financing from the Sponsor or the affiliates of the Sponsor to meet its obligations through the time of liquidation or the completion of the initial Business Combination.

Industry Context

StockSavvy.ai notes that Perceptive Capital Solutions Corp's strategic focus on the healthcare industry, particularly the life sciences and medical technology sectors, aligns with a robust and expanding market, with U.S. national health expenditures reaching approximately $5.3 trillion in 2024. The company's SPAC model, underpinned by a management team with extensive experience from Perceptive Advisors and prior ARYA SPACs, aims to offer a streamlined pathway for private healthcare companies to access public markets, addressing the high demand and often oversubscribed nature of traditional life sciences IPOs. The proposed merger with Freenome, a clinical-stage biotechnology company, positions PCSC within the high-growth diagnostics and therapeutics segment, a key area of innovation in healthcare.

Comparison to Industry Standards

• The management team's prior SPAC ventures, such as ARYA Sciences Acquisition Corp. (Immatics N.V. trading at $10.50), ARYA Sciences Acquisition Corp II (Cerevel Therapeutics acquired for $45.00), ARYA Sciences Acquisition Corp III (Nautilus Biotechnology, Inc. trading at $2.43), and ARYA Sciences Acquisition Corp IV (Adagio Medical, Inc. trading at $0.96), demonstrate a mixed track record, indicating that while successful exits are possible, SPAC outcomes can be highly variable and past performance is not indicative of future results.
• The $10.00 per share price for the PIPE financing is a common benchmark for SPAC transactions, but the implied Freenome base equity value of $725,000,000 will require thorough evaluation against valuations of comparable public and private companies in the diagnostics and therapeutics sector upon the merger's completion to assess its attractiveness.

Corporate Governance

Legal Proceedings

• No material litigation, arbitration, or governmental proceeding is currently pending or contemplated against the company or any members of its management team in their capacity as such.

Related Party Transactions

• The sponsor paid $25,000 for the issuance of 2,156,250 Founder Shares on March 27, 2024.
• The sponsor purchased 286,250 Private Placement Shares for $2,862,500 simultaneously with the closing of the Initial Public Offering.
• The sponsor transferred 30,000 Founder Shares to each of the company's independent directors (Mark C. McKenna, Kenneth Song, and Harlan W. Waksal) at a price of $0.01 per share in April 2024.
• The company pays the sponsor $15,000 per month for office space, secretarial, and administrative support services, and indemnifies the sponsor and its affiliates, including Perceptive Advisors. $180,000 was incurred and paid for these services in 2025.
• The sponsor loaned the company $154,716 under a Promissory Note to cover IPO expenses, which was fully repaid after the IPO closing.
• The sponsor, affiliates of the sponsor, or officers and directors may provide Working Capital Loans up to $3,000,000, convertible into shares at $10.00 per share, to finance transaction costs or working capital deficiencies. No outstanding borrowings existed as of December 31, 2025.
• Perceptive Life Sciences Master Fund Ltd, a fund managed by Perceptive Advisors (an affiliate of the sponsor), is a PIPE Investor in the $240,000,000 PIPE Financing.

Stakeholder Impact

• **Shareholders**: Public shareholders face potential dilution from the PIPE financing and future equity issuances. They also bear the risk of receiving less than $10.00 per share if the business combination fails and the company liquidates due to potential third-party claims against the Trust Account. The 'going concern' warning directly impacts their investment risk.
• **Employees**: The future role of current management and the target business's management is uncertain post-combination, potentially leading to changes in employment or compensation structures. The New Freenome Equity Incentive Plan aims to incentivize employees of the combined entity.
• **Customers/Suppliers**: The successful completion of the Freenome business combination could lead to increased customer awareness and potentially new business opportunities for the combined entity. Conversely, failure to complete the merger could disrupt potential strategic partnerships.
• **Creditors**: The company's working capital deficit and the 'going concern' warning indicate a heightened risk for creditors, although the sponsor has agreed to indemnify the Trust Account against certain claims to protect public shareholders' redemption amounts.

Next Steps

• Complete the Proposed Freenome Business Combination in the first half of 2026, following shareholder and customary closing conditions.
• File a registration statement on Form S-4 for the Proposed Freenome Business Combination.
• Obtain requisite approvals from Company shareholders and Freenome stockholders for the business combination.
• Effect the Domestication to Delaware and change the company's name to Freenome, Inc. (New Freenome).
• Adopt the New Freenome Equity Incentive Plan in advance of the Closing.
• File a resale registration statement with the SEC within 30 calendar days following the Closing Date, registering the resale of certain shares of New Freenome Common Stock held by or issuable to the parties of the Investor Rights Agreement.

Key Dates

Recommendation

The company is a blank check company (SPAC) with no operational history, and its valuation is entirely tied to the successful completion of its proposed business combination with Freenome. While the announcement of the Freenome merger and a substantial PIPE financing are positive developments, the explicit 'going concern' warning from the auditors and the significant working capital deficit introduce considerable financial uncertainty. The mixed performance of the management team's prior SPACs also suggests a high degree of execution risk. Investors should 'hold' if they are comfortable with the speculative nature of SPACs and believe in the long-term potential of the Freenome merger, but the current financial instability and inherent risks warrant caution rather than a 'buy' recommendation.

Keywords

SPAC, Perceptive Capital Solutions Corp, Freenome, Business Combination, Merger, 10-K, SEC Filing, Healthcare, Life Sciences, Medical Technology, PIPE Financing, Going Concern, Trust Account, Redemption Rights, Corporate Governance, Risk Factors, Cayman Islands, Nasdaq, Financial Reporting, Investment, Biotechnology, Diagnostics